Rapid Medical of Shimon and Ronen Eckhouse raised $ 20 million
The company has developed adjustable stents to develop blockages in the blood vessels in the brain. In the past, it was the only company in the field of brain catheterization,
Rapid Medical, which develops a stent for brain catheterization to treat stroke, announced a $ 20 million financing round. The company was founded in 2008 by Ronen Eckhouse, and his father, Shimon Eckhouse, who founded Lumenis and Syneron in the past, which operate in the field of medical aesthetics.
Rapid Medical has developed a brain stent that can be controlled when it is already inside the blood vessels, so that it fits exactly the size of the blood vessels in which the catheterization is performed. The company has already recorded several million dollars in revenue from the sale of its products in Europe, and through the current round, it is interested in financing the completion of its clinical trial in the US, as well as sales in this territory. Microport has the rights to market the product in China and will be responsible for the regulatory process, which has raised $ 38 million to date, and is marketed in some European countries directly and in several countries through distributors.
Agot, Rocson and current investors also participated in the round. Among the existing investors in the company are BRM Capital, Gefen Medical, Winnovation, Shanghai Israel Fund. Lincoln International Bank helped the company complete the deal.
Ronen Eckhouse says: “When we established the company, the field of catheterization for the treatment of brain stroke was in its infancy, and angiography of the blood vessels in the brain is basically similar to catheterization in case of heart attacks or blockages, except that it is more complex. On the blood vessels, and therefore we developed the stent with the technological patent that allows the catheter doctor to control the size of the stent during the operation. ” “This product allows for the treatment of small blood vessels that other competitors in the market are unable to treat, and therefore allows treatment of most patients.”